Abstract: Bone is one of the common metastatic sites of advanced malignant tumors. Bone metastases not only lead to bone-related events (SRE), such as intractable bone pain and pathological fractures, but also result in the increase of medical costs and the risk of death. Internal radiotherapy with radiopharmaceuticals has the advantages of good curative effect, good targeting, and low toxicity. The radiopharmaceuticals commonly used in the treatment of bone metastases are those that release β-particles and α-particles. The clinical application of radiopharmaceuticals releasing β-particles is mature but has some limitations. In recent years, radiopharmaceuticals releasing α-particles are increasingly used in the treatment of bone metastases, because they have greater advantages in relieving pain, reducing the incidence of SRE, and prolonging overall survival than radiopharmaceuticals releasing β-particles. In this work, the authors review the progress in the application of α-particle radiopharmaceuticals in the treatment of bone metastases.